search
Back to results

Affective Effects of Pre-surgery Opioids: a Randomized, Doubleblind Placebo-controlled Trial (AFFECT2)

Primary Purpose

Opioid Use, Affective Symptoms

Status
Recruiting
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
Placebo
Morphine 2.5 mg i.v.
Morphine 5 mg i.v.
Morphine 10 mg i.v.
Oxycodone 2.5 mg i.v.
Oxycodone 5 mg i.v.
Oxycodone 10 mg i.v.
Fentanyl 0.025 mg i.v.
Fentanyl 0.05 mg i.v.
Fentanyl 0.1 mg i.v.
Sponsored by
Oslo University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Opioid Use

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: - Health status ASA1 (American Society of Anesthesiologists physical status) or ASA2 as categorised by a medical doctor at the hospital based on medical history, physical examination, laboratory test etc. unrelated to the current study. ASA1 and ASA2 (ASA1 is defined as "Healthy, non-smoking, no or minimal alcohol use" and ASA2 is defined as "Mild diseases only without substantive functional limitations). Being eligible for day surgery means participants are overtly healthy as determined by clinical staff. The participant is considered as eligible for the use of fentanyl, morphine and oxycodone by a medical doctor at the hospital, based on an overall assessment of the psychiatric and somatic condition, used medical drugs, regarding possible interactions and contraindications for the use of the study medicaments. Body weight and body mass index (BMI) within the range 18-35 kg/m2 (inclusive). Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Having good verbal communication skills in Norwegian. Patients undergoing planned day surgery with general anesthesia (outpatient sample). Orthopedic, rectal, gynecological, hand and foot surgery, and minor vascular procedures. Inpatients undergoing planned gynecological and orthopedic surgery. Hysterectomy, laparoscopic ovariectomy, lumbal herniotomy and other related procedures. Minor gastrointestinal surgery Exclusion Criteria: Known allergic reactions to morphine, oxycodone,or fentanyl. Known allergic reactions to any of the incredients described in the SPC, pt 6.1. Severe chronic obstructive lung disease, Cor pulmonale, Severe bronchial asthma, Severe respiratory failure with hypoxemia and hypercapnia Moderate to severe hepatic impairment, Moderate to severe kidney failure Acute abdomen Increased brain pressure Head trauma Use of MAO blockers in the last two weeks Hypovolemia Hypotension Myasthenia gravis Any other health status not corresponding to ASA1 or ASA2. This includes patients with severe disease burden, major psychiatric disorders that could interfere with the procedures and communication. Pregnancy. Women of childbearing potential defined as all premenopausal female (a postmenopausal state is defined as no menses for 12 months without an alternative medical cause) will be asked if they are pregnant. Breastfeeding women. Illegal drugs use like opioids, cocaine and amphetamine

Sites / Locations

  • Harald LenzRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Placebo

Morphine 2.5 mg

Morphine 5 mg

Morphine 10 mg

Oxycodone 2.5 mg

Oxycodone 5 mg

Oxycodone 10 mg

Fentanyl 0.025 mg

Fentanyl 0.05 mg

Fentanyl 0.1 mg

Arm Description

The patient is given standardized questions about their well-being and affective state before and after the administration of placebo (0.9% NaCl intravenously). This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 2.5 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously. This is carried out on the operating table right before anesthesia

The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously. This is carried out on the operating table right before anesthesia

Outcomes

Primary Outcome Measures

Anxious
Asking the patient of feeling anxious; Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=not anxious and 10=feeling extremely anxious
Relaxed
Asking the patient of feeling relaxed. Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=not relaxed and 10=very relaxed.
Pain level
Asking the patient of pain level. Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=no pain and 10= worst pain imaginable
Good
Asking the patient of feeling good. Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=feeling no good and 10= feeling very good.
Dizzy
Asking the patient of feeling dizzy. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not dizzy and 10=feeling very dizzy.
Sedated
Asking the patient of feeling sedated. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not sedated and 10=feeling very sedated.
Feeling high, Numeric rating scale 0 -10
Asking the patient of feeling high. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not high and 10=feeling very high.
Euphoric
Asking the patient of feeling high. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not euphoric and 10=feeling very euphoric.
Drug liking
Asking the patient of drug liking. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not drug liking and 10=feeling very drug liking.
Drug disliking
Asking the patient of drug disliking. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not drug disliking and 10=feeling very drug disliking.

Secondary Outcome Measures

Full Information

First Posted
November 17, 2022
Last Updated
September 14, 2023
Sponsor
Oslo University Hospital
Collaborators
Vestre VikenHF Kongsberg Sykehus
search

1. Study Identification

Unique Protocol Identification Number
NCT05639712
Brief Title
Affective Effects of Pre-surgery Opioids: a Randomized, Doubleblind Placebo-controlled Trial
Acronym
AFFECT2
Official Title
Understanding Opioid Use Before and After Surgery in Norway: A Prospective Multicenter Study and Randomized Double-blind Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 13, 2022 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
Collaborators
Vestre VikenHF Kongsberg Sykehus

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To investigate and compare the affective short-term effects of opioid drugs: morphine, oxycodone and fentanyl, administered to the patients before the induction of general anesthesia. Charting opioid use after surgery in patients treated at hospitals in Norway Identify predictors for postoperative opioid use and persistent pain
Detailed Description
The aim of the present study is to assess and compare, with a randomized, double-blind placebo-controlled trial, the affective effects of three commonly used opioid analgesics (Morphine, oxycodone and fentanyl) administered in three different doses before surgery in a clinical setting associated with physiological and psychological stress. As a starting point, we have conducted an observational quality control study on peri-operative opioid pain management in day surgery patients. Quality control study - a pilot study In this observational quality control study, we measured acute effects of the opioid agonist Remifentanil (effect site concentration 5ng/ml, Minto model) in day surgery patients on the operating table at Kongsberg hospital. Patients rated their levels of "feeling good" and "anxious" on a 0-10 numerical rating scale (NRS) immediately before and 1 minute after receiving remifentanil infusion. They also rated drug-specific effects such as "feeling high", "liking the drug effects" and their "level of drug-related discomfort". Moreover, we collected data on postoperative opioid use and pain during recovery through a telephone interview on the day following the surgery. The study was conducted with the usual standard hospital treatment and as such, did not interfere with the patients' medical procedures. All the procedures were approved by the data protection officer at Kongsberg Hospital, and all included patients signed informed consent on the day of surgery. In the weeks prior to surgery participants received a questionnaire to assess their pain levels, nervousness and demographics as part of the hospital's standard procedure. On the day of surgery, approximately 30 min before surgery (T2) patients were asked to fill in questionnaires to assess mood, pain and prior opioid use. One minute before and one minute after opioid ( administration (T3), the patient was asked to rate mood, anxiety, drug liking and drug related discomfort. On the day following surgery patients were contacted by phone to assess their mood, pain and pain interference, as well as their pain relief strategies in the last 24h (e.g. use of provided analgesics). 160 patients were included in the pilot quality control study. The results of the pilot study show that patients report a clear feeling of 'drug high' after remifentanil infusion. Surprisingly, however, the opioid analgesic induced only a weak reduction of anxiety, and the majority of patients reported feeling worse or equally good, but not better, after the infusion. In the postoperative phone interview, many patients tell us they have not used any of the opioid drugs prescribed for at-home pain relief during the first 24 hours are recovering at home. Stated reasons include a fear of addiction, as well as a wish to keep the analgesics in case of breakthrough/peak pain at a later stage. These preliminary results do not support the opioid pre-induction procedure as an effective manner to produce pre-surgery stress relief. It might be possible that the subjective perception of stress relief does not match the physiological relief reaction to stress. On the basis of these intriguing, preliminary findings, we will now conduct a more comprehensive randomized double-blind controlled study comparing different classes of pre-surgical opioid analgesics on the subjective and physiological affective reactions in an acute stress clinical situation in Norway. Possible participants of the AFFECT2 RCT (randomized controlled trial) will also be asked if they wish to join a parallel longitudinal study conducted in collaboration with the University of Oslo (UiO) in which we will collect and analyse data on relevant pre-surgery risk factors for problematic opioid use, and to quantify opioid-induced analgesia before and after surgery using prescription registry data.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Use, Affective Symptoms

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
The patient will be randomized to 1 of 10 arms: Placebo (saline 0.9%), morphine 2.5 - 5 - 10 mg, oxycodone 2.5 - 5 -10 mg, or fentanyl 0.025 - 0.05 - 0.1 mg iv.
Masking
ParticipantInvestigator
Masking Description
Randomization sequences will be generated prior to the first enrolment of the amended protocol by an independent group (Clinical trails unit- OUS) not affiliated with the present study. The drug will be prepared after opening an opaque envelope on the day of surgery by a nurse not participating in the study. The syringe with the drug will be labeled with a code number and handed to the study nurse or doctor.
Allocation
Randomized
Enrollment
1000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of placebo (0.9% NaCl intravenously). This is carried out on the operating table right before anesthesia
Arm Title
Morphine 2.5 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Morphine 5 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Morphine 10 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Oxycodone 2.5 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Oxycodone 5 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Oxycodone 10 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Fentanyl 0.025 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Fentanyl 0.05 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously. This is carried out on the operating table right before anesthesia
Arm Title
Fentanyl 0.1 mg
Arm Type
Active Comparator
Arm Description
The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously. This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
0.9% NaCl , Natriumklorid 9 mg/ml, Hameln (ATC code: B05B B01)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Morphine 2.5 mg i.v.
Other Intervention Name(s)
Morphine, Orion (ATC code: N02A A01)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Morphine 5 mg i.v.
Other Intervention Name(s)
Morphine, Orion (ATC code: N02A A01)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Morphine 10 mg i.v.
Other Intervention Name(s)
Morphine, Orion (ATC code: N02A A01)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Oxycodone 2.5 mg i.v.
Other Intervention Name(s)
Oxycodone, Hameln (ATC code: N02A A05)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Oxycodone 5 mg i.v.
Other Intervention Name(s)
Oxycodone, Hameln (ATC code: N02A A05)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Oxycodone 10 mg i.v.
Other Intervention Name(s)
Oxycodone, Hameln (ATC code: N02A A05)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Fentanyl 0.025 mg i.v.
Other Intervention Name(s)
Fentanyl, Hameln (ATC code: N01A H01)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Fentanyl 0.05 mg i.v.
Other Intervention Name(s)
Fentanyl, Hameln (ATC code: N01A H01)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
Intervention Type
Drug
Intervention Name(s)
Fentanyl 0.1 mg i.v.
Other Intervention Name(s)
Fentanyl, Hameln (ATC code: N01A H01)
Intervention Description
The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
Primary Outcome Measure Information:
Title
Anxious
Description
Asking the patient of feeling anxious; Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=not anxious and 10=feeling extremely anxious
Time Frame
8-10 minutes
Title
Relaxed
Description
Asking the patient of feeling relaxed. Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=not relaxed and 10=very relaxed.
Time Frame
8-10 minutes
Title
Pain level
Description
Asking the patient of pain level. Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=no pain and 10= worst pain imaginable
Time Frame
8-10 minutes
Title
Good
Description
Asking the patient of feeling good. Numeric rating scale 0 -10 prior opioid and post opioid intravenously (or placebo). 0=feeling no good and 10= feeling very good.
Time Frame
8-10 minutes
Title
Dizzy
Description
Asking the patient of feeling dizzy. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not dizzy and 10=feeling very dizzy.
Time Frame
2-4 minutes
Title
Sedated
Description
Asking the patient of feeling sedated. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not sedated and 10=feeling very sedated.
Time Frame
2-4 minutes
Title
Feeling high, Numeric rating scale 0 -10
Description
Asking the patient of feeling high. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not high and 10=feeling very high.
Time Frame
2-4 minutes
Title
Euphoric
Description
Asking the patient of feeling high. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not euphoric and 10=feeling very euphoric.
Time Frame
2-4 minutes
Title
Drug liking
Description
Asking the patient of drug liking. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not drug liking and 10=feeling very drug liking.
Time Frame
2-4 minutes
Title
Drug disliking
Description
Asking the patient of drug disliking. Numeric rating scale 0-10 post opioid intravenously (or placebo). 0=feeling not drug disliking and 10=feeling very drug disliking.
Time Frame
2-4 minutes
Other Pre-specified Outcome Measures:
Title
Heart rate
Description
beats/min prior opioid and post opioid intravenously
Time Frame
10 min
Title
Heart rate variability
Description
Heart rate variability (HRV) prior opioid and post opioid intravenously
Time Frame
10 min

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Health status ASA1 (American Society of Anesthesiologists physical status) or ASA2 as categorised by a medical doctor at the hospital based on medical history, physical examination, laboratory test etc. unrelated to the current study. ASA1 and ASA2 (ASA1 is defined as "Healthy, non-smoking, no or minimal alcohol use" and ASA2 is defined as "Mild diseases only without substantive functional limitations). Being eligible for day surgery means participants are overtly healthy as determined by clinical staff. The participant is considered as eligible for the use of fentanyl, morphine and oxycodone by a medical doctor at the hospital, based on an overall assessment of the psychiatric and somatic condition, used medical drugs, regarding possible interactions and contraindications for the use of the study medicaments. Body weight and body mass index (BMI) within the range 18-35 kg/m2 (inclusive). Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Having good verbal communication skills in Norwegian. Patients undergoing planned day surgery with general anesthesia (outpatient sample). Orthopedic, rectal, gynecological, hand and foot surgery, and minor vascular procedures. Inpatients undergoing planned gynecological and orthopedic surgery. Hysterectomy, laparoscopic ovariectomy, lumbal herniotomy and other related procedures. Minor gastrointestinal surgery Exclusion Criteria: Known allergic reactions to morphine, oxycodone,or fentanyl. Known allergic reactions to any of the incredients described in the SPC, pt 6.1. Severe chronic obstructive lung disease, Cor pulmonale, Severe bronchial asthma, Severe respiratory failure with hypoxemia and hypercapnia Moderate to severe hepatic impairment, Moderate to severe kidney failure Acute abdomen Increased brain pressure Head trauma Use of MAO blockers in the last two weeks Hypovolemia Hypotension Myasthenia gravis Any other health status not corresponding to ASA1 or ASA2. This includes patients with severe disease burden, major psychiatric disorders that could interfere with the procedures and communication. Pregnancy. Women of childbearing potential defined as all premenopausal female (a postmenopausal state is defined as no menses for 12 months without an alternative medical cause) will be asked if they are pregnant. Breastfeeding women. Illegal drugs use like opioids, cocaine and amphetamine
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gernot Ernst, MD, PhD
Phone
+4748072777
Email
bserng@vestreviken.no
First Name & Middle Initial & Last Name or Official Title & Degree
Harald Lenz, MD, PhD
Phone
+4790549545
Email
harald.lenz@medisin.uio.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gernot Ernst, MD,PhD
Organizational Affiliation
Kongsberg Hospital, Vestre Viken Health Trust Norway
Official's Role
Principal Investigator
Facility Information:
Facility Name
Harald Lenz
City
Oslo
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Harald Lenz, PhD
Phone
004790549545
Email
harald.lenz@medisin.uio.no
First Name & Middle Initial & Last Name & Degree
Leiv Arne Rosseland, PhD
Phone
004792204274
Email
l.a.rosseland@medisin.uio.no

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22713632
Citation
Angst MS, Lazzeroni LC, Phillips NG, Drover DR, Tingle M, Ray A, Swan GE, Clark JD. Aversive and reinforcing opioid effects: a pharmacogenomic twin study. Anesthesiology. 2012 Jul;117(1):22-37. doi: 10.1097/ALN.0b013e31825a2a4e.
Results Reference
background
Citation
Astuto, M., & Lauretta, D. (2009). Anesthesia Induction. In M. Astuto (Ed.), Basics (pp. 85-99). Milano: Springer Milan.
Results Reference
background
PubMed Identifier
29673620
Citation
Bershad AK, Miller MA, Norman GJ, de Wit H. Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans. Horm Behav. 2018 Jun;102:41-47. doi: 10.1016/j.yhbeh.2018.04.009. Epub 2018 Apr 24.
Results Reference
background
PubMed Identifier
20444310
Citation
Bjerkeset O, Romild U, Smith GD, Hveem K. The associations of high levels of C-reactive protein with depression and myocardial infarction in 9258 women and men from the HUNT population study. Psychol Med. 2011 Feb;41(2):345-52. doi: 10.1017/S0033291710000887. Epub 2010 May 6.
Results Reference
background
PubMed Identifier
31462812
Citation
Choudhary P, Dutta A, Sethi N, Sood J, Rai D, Gupta M. Pre-induction fentanyl dose-finding study for controlled hypotension during functional endoscopic sinus surgery. Indian J Anaesth. 2019 Aug;63(8):653-659. doi: 10.4103/ija.IJA_866_18.
Results Reference
background
PubMed Identifier
20530588
Citation
Colasanti A, Rabiner EA, Lingford-Hughes A, Nutt DJ. Opioids and anxiety. J Psychopharmacol. 2011 Nov;25(11):1415-33. doi: 10.1177/0269881110367726. Epub 2010 Jun 8.
Results Reference
background
Citation
Courtwright, D. T. (2001). Dark Paradise: A History of Opiate Addiction in America. Cambridge MA: Harvard University Press.
Results Reference
background
PubMed Identifier
21708856
Citation
Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011 Jul;25(5):494-503. doi: 10.1177/0269216310384902.
Results Reference
background
PubMed Identifier
30273897
Citation
Deighton S, Neville A, Pusch D, Dobson K. Biomarkers of adverse childhood experiences: A scoping review. Psychiatry Res. 2018 Nov;269:719-732. doi: 10.1016/j.psychres.2018.08.097. Epub 2018 Aug 25.
Results Reference
background
PubMed Identifier
30521692
Citation
Doleman B, Leonardi-Bee J, Heinink TP, Bhattacharjee D, Lund JN, Williams JP. Pre-emptive and preventive opioids for postoperative pain in adults undergoing all types of surgery. Cochrane Database Syst Rev. 2018 Dec 3;12(12):CD012624. doi: 10.1002/14651858.CD012624.pub2.
Results Reference
background
PubMed Identifier
22554450
Citation
Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, Riley J, Dahan A. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013 Jan;75(1):60-78. doi: 10.1111/j.1365-2125.2012.04317.x.
Results Reference
background
PubMed Identifier
30234925
Citation
Dutta A, Sethi N, Choudhary P, Sood J, Panday BC, Chugh PT. The impact of preinduction fentanyl dosing strategy on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. J Opioid Manag. 2018 Jul/Aug;14(4):283-293. doi: 10.5055/jom.2018.0460.
Results Reference
background
PubMed Identifier
11224325
Citation
Evans SM, Foltin RW, Levin FR, Fischman MW. Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol. 1995 Mar;6(2):176-186.
Results Reference
background
PubMed Identifier
23988582
Citation
Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO. The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2597-607. doi: 10.1016/j.neubiorev.2013.08.006. Epub 2013 Aug 26.
Results Reference
background
Citation
Helsedirektoratet. (2018). Utvikling og variasjon i kirurgisk behandling 2013-2017. Retrieved from Oslo:
Results Reference
background
PubMed Identifier
30915981
Citation
Levy N, Mills P. Controlled-release opioids cause harm and should be avoided in management of postoperative pain in opioid naive patients. Br J Anaesth. 2019 Jun;122(6):e86-e90. doi: 10.1016/j.bja.2018.09.005. Epub 2018 Oct 19. No abstract available.
Results Reference
background
PubMed Identifier
28550985
Citation
Li PH, Ue KL, Wagner A, Rutkowski R, Rutkowski K. Opioid Hypersensitivity: Predictors of Allergy and Role of Drug Provocation Testing. J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1601-1606. doi: 10.1016/j.jaip.2017.03.035. Epub 2017 May 24.
Results Reference
background
PubMed Identifier
24295876
Citation
Martel MO, Dolman AJ, Edwards RR, Jamison RN, Wasan AD. The association between negative affect and prescription opioid misuse in patients with chronic pain: the mediating role of opioid craving. J Pain. 2014 Jan;15(1):90-100. doi: 10.1016/j.jpain.2013.09.014. Epub 2013 Oct 12.
Results Reference
background
PubMed Identifier
27058161
Citation
McHugh RK, Weiss RD, Cornelius M, Martel MO, Jamison RN, Edwards RR. Distress Intolerance and Prescription Opioid Misuse Among Patients With Chronic Pain. J Pain. 2016 Jul;17(7):806-14. doi: 10.1016/j.jpain.2016.03.004. Epub 2016 Apr 4.
Results Reference
background
PubMed Identifier
23271193
Citation
Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl). 2013 May;227(1):177-92. doi: 10.1007/s00213-012-2954-z. Epub 2012 Dec 28.
Results Reference
background
PubMed Identifier
26516465
Citation
Natusch D. Equianalgesic doses of opioids - their use in clinical practice. Br J Pain. 2012 Feb;6(1):43-6. doi: 10.1177/2049463712437628. No abstract available.
Results Reference
background
PubMed Identifier
29376460
Citation
Naude PJW, Roest AM, Stein DJ, de Jonge P, Doornbos B. Anxiety disorders and CRP in a population cohort study with 54,326 participants: The LifeLines study. World J Biol Psychiatry. 2018 Sep;19(6):461-470. doi: 10.1080/15622975.2018.1433325. Epub 2018 Feb 22.
Results Reference
background
PubMed Identifier
18070849
Citation
Schaffer CB, Nordahl TE, Schaffer LC, Howe J. Mood-elevating effects of opioid analgesics in patients with bipolar disorder. J Neuropsychiatry Clin Neurosci. 2007 Fall;19(4):449-52. doi: 10.1176/jnp.2007.19.4.449.
Results Reference
background
PubMed Identifier
26004818
Citation
Sgoifo A, Carnevali L, Alfonso Mde L, Amore M. Autonomic dysfunction and heart rate variability in depression. Stress. 2015;18(3):343-52. doi: 10.3109/10253890.2015.1045868. Epub 2015 May 25.
Results Reference
background
Citation
Sneader, W. (2005). Drug discovery : a history. Chichester: Wiley.
Results Reference
background
PubMed Identifier
1517629
Citation
Stanley TH. The history and development of the fentanyl series. J Pain Symptom Manage. 1992 Apr;7(3 Suppl):S3-7. doi: 10.1016/0885-3924(92)90047-l.
Results Reference
background
PubMed Identifier
22445418
Citation
Stone AL, Becker LG, Huber AM, Catalano RF. Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav. 2012 Jul;37(7):747-75. doi: 10.1016/j.addbeh.2012.02.014. Epub 2012 Feb 24.
Results Reference
background
PubMed Identifier
28060783
Citation
Thomas EA, Garland EL. Mindfulness is Associated With Increased Hedonic Capacity Among Chronic Pain Patients Receiving Extended Opioid Pharmacotherapy. Clin J Pain. 2017 Feb;33(2):166-173. doi: 10.1097/AJP.0000000000000379.
Results Reference
background
PubMed Identifier
30844399
Citation
Tracey I, Woolf CJ, Andrews NA. Composite Pain Biomarker Signatures for Objective Assessment and Effective Treatment. Neuron. 2019 Mar 6;101(5):783-800. doi: 10.1016/j.neuron.2019.02.019.
Results Reference
background
PubMed Identifier
8882244
Citation
Wang LP, Hermann C, Westrin P. Thiopentone requirements in adults after varying pre-induction doses of fentanyl. Anaesthesia. 1996 Sep;51(9):831-5. doi: 10.1111/j.1365-2044.1996.tb12611.x.
Results Reference
background

Learn more about this trial

Affective Effects of Pre-surgery Opioids: a Randomized, Doubleblind Placebo-controlled Trial

We'll reach out to this number within 24 hrs